Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

The current paper compares the effectiveness of two vs. three doses of these vaccines against Omicron compared to Delta.

25 Jan 2022

Scientists develop a model to rapidly identify vaccine breakthrough SARS-CoV-2 variants

In a new study, scientists have recently developed a computational model to predict the antigenicity and immune escape ability of emerging variants of SARS-CoV-2.

25 Jan 2022

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

A recent study evaluated the sensitivity and specificity of a “spit and mail” serology test.

25 Jan 2022

LA County study finds COVID-19 'herd immunity' unlikely

In a research letter published in the Journal of the American Medical Association (JAMA), researchers carried out a seroprevalence and vaccination coverage study in Los Angeles County (LAC).

24 Jan 2022

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2.

24 Jan 2022

Peptide-enhanced antibody therapy may help treat breast cancer metastasis to bone

A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.

24 Jan 2022

Antibody response 18 months after SARS-CoV-2 infection in vaccinated and unvaccinated individuals

A new study assessed the dynamics of IgG titers over 18 months in patients who had recovered from COVID-19 infections during March 2020.

24 Jan 2022

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.

24 Jan 2022

Vaccine wars ignite in California as lawmakers seek stronger laws

California is poised to become the front line of America's vaccination wars. State lawmakers are drafting the toughest covid-19 vaccine legislation in the country, backed by a new pro-vaccine lobbying force promising to counter anti-vaccine activists who have threatened government officials and shut down public meetings across the state.

24 Jan 2022

Researchers are in the race to beat Omicron

David Veesler and his lab members aren't getting much sleep these days. In the final weeks of 2021, he and his team worked around the clock to post four coronavirus papers on the preprint server bioRxiv.

24 Jan 2022

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

A recent study published in the journal Science brings a detailed chemical and molecular perspective on the improved evasion of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the retention of strong interactions with the receptor as two principal factors underneath the notorious transmissibility of the SARS-CoV-2 Omicron variant.

23 Jan 2022

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United States Food and Drug Administration (FDA) for their in vitro potency against several SARS-CoV-2 variants, including the currently dominant Omicron train.

23 Jan 2022

Novel SARS-CoV-2 mutations reported in chronic HIV patients

A new study describes the emergence of new SARS-CoV-2 variants in three immunocompromised patients.

23 Jan 2022

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Researchers describe the state of adaptive immunity following vaccination with the Pfizer-BioNTech BNT162b2 COVID-19 vaccine.

23 Jan 2022

Impact of booster vaccines against SARS-CoV-2 Omicron variant

Researchers explore the dynamics of COVID-19 vaccine-induced protection against SARS-CoV-2 variants of concern.

23 Jan 2022

Many care home residents, staff tested positive for Covid-19 during the first two waves of the pandemic

More than a third of care home residents and a quarter of care home staff in England showed evidence of infection with SARS-CoV-2 during the first two waves of the pandemic, according to a new study led by UCL (University College London) researchers.

22 Jan 2022

Researchers design neural network to predict severity of COVID-19 variants

In a new study, researchers predict the risk of infection with severe coronavirus disease 2019 from the sequence of the spike protein.

21 Jan 2022

Vaccines alone are ineffective against the widely circulating Omicron variant

Millions of people around the world have received two shots of Sinovac, a Chinese-manufactured inactive vaccine that is used in 48 countries to help reduce transmission rates of COVID-19.

21 Jan 2022

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

In a new study, researchers assessed the efficacy of the FDA-approved therapeutic mAbs, as well as to small-molecule antiviral agents against the SARS-CoV-2 Omicron variant in Syrian hamsters.

21 Jan 2022

Study suggests SARS-CoV-2 Omicron variant spike mediated immune escape and tropism shift

A new study showed that the SARS-CoV-2 Omicron spike binds to its receptor with enhanced affinity and yet evades vaccine-elicited neutralizing antibodies and that a booster mRNA vaccine broadened the neutralization of Omicron.

21 Jan 2022

Antibody News and Research

Further Reading

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

Scientists develop a model to rapidly identify vaccine breakthrough SARS-CoV-2 variants

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

LA County study finds COVID-19 'herd immunity' unlikely

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

Peptide-enhanced antibody therapy may help treat breast cancer metastasis to bone

Antibody response 18 months after SARS-CoV-2 infection in vaccinated and unvaccinated individuals

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Vaccine wars ignite in California as lawmakers seek stronger laws

Researchers are in the race to beat Omicron

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

Novel SARS-CoV-2 mutations reported in chronic HIV patients

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Impact of booster vaccines against SARS-CoV-2 Omicron variant

Many care home residents, staff tested positive for Covid-19 during the first two waves of the pandemic

Researchers design neural network to predict severity of COVID-19 variants

Vaccines alone are ineffective against the widely circulating Omicron variant

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

Study suggests SARS-CoV-2 Omicron variant spike mediated immune escape and tropism shift

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo